Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555063 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAKMT2ACYP3A4DRD2 | |
| SCHEMBL1555334 | 0.79 | NOS2 (0.43) | SMN1; SMN2LMNAKMT2ADRD2DRD4 | |
| SCHEMBL1555061 | 0.78 | CYP3A4 (0.40) | SMN1; SMN2LMNAKMT2ACYP3A4DRD2 | |
| SCHEMBL1555855 | 0.77 | DRD2 (0.40) | SMN1; SMN2LMNAKMT2ACYP3A4DRD2 | |
| SCHEMBL14503449 | 0.77 | CYP3A4 (0.38) | SMN1; SMN2LMNAKMT2ACYP3A4SLC6A4 | |
| SCHEMBL5370770 | 0.72 | DRD2 (0.37) | SMN1; SMN2LMNAKMT2ACYP3A4DRD2 | |
| SCHEMBL5373601 | 0.72 | DRD2 (0.37) | SMN1; SMN2LMNAKMT2ACYP3A4DRD2 | |
| SCHEMBL5377182 | 0.72 | LMNA (0.38) | SMN1; SMN2LMNAKMT2ACYP3A4DRD2 | |
| SCHEMBL1555103 | 0.70 | SCN4A (0.48) | DRD2DRD4DRD3SCN4AALDH1A1 | |
| SCHEMBL1555845 | 0.70 | CYP3A4 (0.42) | SMN1; SMN2LMNAKMT2ACYP3A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | claimed |
| US-20120316247-A1 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | THE GENERAL HOSPITAL CORPORATION (US) | 2012-12-13 | — | — | US | disclosed |
| US-7217701-B2 | Intracellular calcium concentration increase inhibitors | KATSUHIKO MIKOSHIBA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316247-A1 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | CHAT, ACHE, BCHE | SMN1; SMN2 991/4885LMNA 2851/4885KMT2A 3198/4885 |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | CAB39, BPGM, ORAI1 | SMN1; SMN2 1141/4885LMNA 4015/4885KMT2A 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.